CRISPR Cuts
VitenskapWelcome to the CRISPR revolution. Take a break and join us as we guide conversations with an expert CRISPR cast about this cutting-edge science.
Siste episoder av CRISPR Cuts podcast
- Imran House and Junyun Lai Discuss CRISPR Screening in Immuno-Oncology (00:26:06)
Imran House, Ph.D. and Junyun Lai Ph.D. are Senior Scientists at the biotech start-up, oNKo-Innate in Melbourne, Australia that focuses on developing immuno-oncology therapies. In this episode, they discussed what they do at oNKo-innate, their career transitions from leaving academics to entering the biotech industry, and how CRISPR is impacting cancer-immunotherapy development. They also discussed overcoming common obstacles faced when developing cytokine therapies and future outlooks on clinical trials using these kinds of therapies. Reach out and connect with both Imran and Junyun on social media platforms: Imran House, Ph.D. LinkedIn X: @ImranHouse Junyun Lai, Ph.D. LinkedIn X: @JunyunLai
- Mark DeWitt and Don Kohn Discuss Their ex vivo CRISPR-based Therapy to Cure Sickle Cell Anemia (00:33:24)
Dr. Mark DeWitt Ph.D., Associate Director at Mammoth Biosciences, and Dr. Don Kohn M.D., distinguished professor and Director of the UCLA Human Gene and Cell Therapy Program and CIRM grantee sat down with us to discuss their latest clinical trials to cure sickle cell anemia, how synthetic guides accelerated their journey from the bench to the clinic, and their experience in the cell and gene therapy space.
- Dina Simkin Breaks Down Epilepsy Cell Modeling (00:27:24)
Dina Simkin, Professor of Neurology at Northwestern University, joins us in this episode of CRISPR Cuts. Dr. Simkin talks about her path to becoming a researcher, art, and the importance of patient and isogenic iPSC models to study genetically linked forms of epilepsies.
- Sunil Sharma and Raffaella Soldi Talk CRISPR For Unbiased Drug Screening for Rare Pediatric Cancers (00:24:43)
Dr. Sunil Sharma and Dr. Raffaella Soldi of the Translational Genomics Research Institute chat about using CRISPR arrayed screens to identify novel drug targets for Ewing's Sarcoma, outlooks for the future of cancer therapies, and the Arizona heat.
- Stephanie Cherqui Discusses Clinical Development of CRISPR Therapies for Rare Diseases (00:20:27)
Professor Stephanie Cherqui, UCSD, has worked on the development of cell therapies for two rare genetic diseases, cystinosis and Friedreich’s ataxia. In this interview, Dr. Cherqui chats about her experience working on rare diseases, developing a CRISPR-edited therapy for Friedreich's ataxia, navigating regulatory challenges in cell and gene therapies, and more.
- Christian Groendahl On Pioneering a CRISPR-based Microbial Gene Therapy (00:29:11)
Tune in to hear Christian Groendahl, CEO of SNIPR Biome, talk about CRISPR editing in prokaryotes, their novel E. coli-targeting CRISPR therapy trials, and his experiences and vision leading a start up.
- Bryan Dechairo Envisions an Accessible Future for CRISPR Diagnostics (00:35:29)
In this episode, Bryan Dechairo, CEO of Sherlock Biosciences, talks about the impact of technology advances in the field of CRISPR diagnostics, his experiences leading Sherlock Biosciences, and his team’s mission of accessibility.
- Ayal Hendel Talks About CRISPR in Bubble Boy Disease (00:35:46)
Dr. Ayal Hendel, a genome-editing pioneer and group leader at Bar Ilan University in Israel, was one of the first researchers to use modified synthetic sgRNA to edit primary cells with CRISPR. In this episode, Dr. Hendel shares his perspectives on the recent CRISPR advancements and his work on the bubble boy disease.
- Jimi Olaghere Opens up About His Sickle Cell Disease and CRISPR Trial (00:39:59)
Jimi has dealt with sickle cell disease, a genetic disorder with serious implications, his entire life. Undergoing a CRISPR gene editing trial turned his hope for a cure into reality with promising results from the early phases. Tune in to learn about Jimi's journey in this episode.
- TJ Cradick Speaks About Their HIV CRISPR Therapy in Trials (00:23:40)
TJ Cradick, Chief Scientific Officer at Excision Bio, discusses their CRISPR HIV therapy that recently proceeded into clinical trials in this episode and their ongoing work on other viral diseases.
- Bryce Olson Relays His Experience on Personalized Therapies for Cancer Patients (00:42:37)
After being diagnosed with aggressive prostate cancer, Bryce Olson quickly learned the science behind it and has leveraged NGS to understand his tumor genomics and find opportunities in personalized therapies. Hear the patient perspective for the first time on our podcast through Bryce's narration of his experience and pursuit of next generation cell and gene therapies.
- Neville Sanjana Discusses Ways to Enhance CRISPR-Cas13 Knockdown in Human Cells (00:32:52)
In this collaboration episode with NEB, we interview Dr. Neville Sanjana, a core faculty member at the New York Genome Center, about his recent publication in which chemically modified guide RNAs were used to enhance CRISPR-Cas13 knockdown in human cells.
- Kiana Aran Chats About her Nature Award and New Non-Profit (00:41:09)
In this episode, we chat with Dr. Kiana Aran, the CSO of Cardea Bio and associate professor at Keck Graduate Institute, who recently won the Nature Research Award for Inspiring Women in Science. Dr. Aran talks about her experience being a nominee and award winner, her early days and scientific journey, and the launch of her new non-profit, Aran Nebula.
- 6 Women CRISPR Leaders Get Candid About Their Journeys to the Top (01:02:44)
We chatted with six female leaders in the CRISPR—Alison van Eenennaam, Ph.D., Kiana Aran, Christina Trojel-Hansen, Ph.D., Laura Lambert, Ph.D., Elena Miñones Moyano, Ph.D., and Samantha Maragh, Ph.D.— about their professional journeys. Tune in to this episode for a candid and honest discussion on a broad range of topics, including their experiences as women of color, life as working moms, adjusting in male-dominated fields, experiences being part of the LGBTQIA community, and the role of mentors in professional development.
- Jesse Boehm Discusses Tackling Rare Cancers Using CRISPR (00:30:35)
In this CRISPR Cuts episode, Dr. Jesse Boehm, the Chief Scientific Officer of the Break Through Cancer Foundation and principal investigator at the Broad Institute, talks about his work on rare cancers. He also covers how CRISPR technology is transforming cancer research.
- NIH Scientists Discuss the iNDI Project for Alzheimer's Disease Modeling (00:37:14)
The Inducible Pluripotent Stem Cell Neurodegeneration Initiative (iNDI), an NIH effort, aims to standardize disease models for Alzheimer’s and related dementias. Hear the principal contributors, Dr. Michael E. Ward and Dr. Mark R. Cookson, scientists at the NIH, talk about the inception of the iNDI project, the challenges and opportunities, and the future of neurodegenerative research.
- Joe Miano Talks About Prime Editing in Mice (00:19:41)
Prime editing is a new genome engineering tool that emerged just a couple of years back. Right from the get-go, this technology made waves as a potential alternative to CRISPR. Now, the first comparative study in mice is out. Dr. Joe Miano, Professor at the Augusta University in Georgia, talks about their collaborative work comparing traditional CRISPR-mediated homology-directed repair with prime editing in mice.
- IGI Researchers Are Using CRISPR to Reduce Cyanide in Cassava (00:26:30)
Did you know cassava can cause cyanide poisoning if it is not processed correctly and consumed with a protein-poor diet? In this episode, we chat with IGI researchers, Jess Lyons and Michael Gomez about their work on using CRISPR to reduce cyanide in cassava and improve its food safety.
- Kevin Davies Chats About His Latest Book "Editing Humanity" (00:32:13)
Kevin Davies, the executive editor of The CRISPR Journal, has closely watched the genetics space evolve over the last decades. His expertise and experience were the perfect foundation for his latest book "Editing Humanity: The CRISPR Revolution and the New Era of Genome Editing." In this episode, Kevin discusses his motivation for the book, along with some behind-the-scenes stories when writing this timely literature piece.
- Michael Friend Advocates For Diversity in CRISPR (00:18:52)
In this episode, Michael Friend, CEO of Minority Coalition for Precision Medicine, discusses the lack of diversity in genome editing field and covers potential solutions for ensuring an inclusive future, particularly for black scientists.
- CRISPR Forecast 2021 with Paul Dabrowski and Robert Deans (00:17:49)
In this episode, Paul Dabrowski, CEO of Synthego, and Robert Deans, CSO of Synthego, discuss the CRISPR silver linings of 2020 and predict the directions and milestones for gene editing in 2021.
- CRISPR Office Hours with Hamid Ghanadaan (00:35:58)
The COVID-19 pandemic is a unique situation for lab scientists, many of whose work has come to a standstill. Hamid Ghanadaan, CEO of Linus, discusses the impact of COVID-19 on science and the next steps for scientists, based on their survey of >1000 scientists.
- Ryan Pawell Talks About Indee Labs’ CRISPR Delivery Technology for Affordable Immunotherapies (00:12:59)
The mission of Indee Labs, a Berkeley biotech, is to deliver CRISPR reagents into cells using microfluidics for developing affordable cell and gene therapies in the future. We interviewed Ryan Pawell, Founder and CEO of Indee Labs, about the concept of using microfluidics for CRISPR delivery, their mission and ongoing projects, and the convergence of engineering and biology for building scalable platforms.
- Making of a CRISPR Film: Behind the Scenes with Producers of Human Nature (00:37:33)
What is the process to make a science film? In this episode, Sarah Goodwin and Elliot Kirschner, producers of Human Nature, a documentary on CRISPR, offer glimpses into making of the film.
- Leading St. Jude's Genome Engineering Capabilities: A Chat with Shondra Miller (00:10:13)
Shondra Miller shares her experience of starting a shared genome engineering resource at the St. Jude Children's Research Hospital. Learn more about her research projects and her views on the past, present, and future of the genome editing field in this podcast episode.